NasdaqGS:RVMDBiotechs
Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid
Revolution Medicines previously announced that the U.S. FDA accepted for review its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma, supported by Phase 3 RASolute 302 data showing improved overall and progression-free survival versus standard chemotherapy.
The drug’s Breakthrough Therapy and Orphan Drug designations, together with inclusion in the FDA Commissioner’s National Priority Voucher...